Serono Pharmaceutical Research Institute

Summary

Organization: Serono Pharmaceutical Research Institute
Country: Switzerland

Top Publications

  1. ncbi Treatment strategies in assisted reproduction for women of advanced maternal age
    Colin M Howles
    Serono International SA, Department of Product Development, Geneva, Switzerland
    Int Surg 91:S37-54. 2006
  2. ncbi Computational characterization of proteins
    Jadwiga Bienkowska
    Serono Reproductive Biology Institute, One Technology Pl, Rockland, MA 02370, USA
    Expert Rev Proteomics 2:129-38. 2005
  3. ncbi Bioequivalence of liquid and freeze-dried recombinant human follicle-stimulating hormone
    I Lugan
    International SA, R and Ph Development HPG, Geneva, Switzerland
    Curr Med Res Opin 21:121-5. 2005
  4. ncbi Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH
    R M Bassett
    Global Product Development Unit, Serono International SA, Geneva, Switzerland
    Reprod Biomed Online 10:169-77. 2005
  5. ncbi Flow cytometric analysis of CD41-labeled platelets isolated by the rapid, one-step OptiPrep method from human blood
    Krisztina Bagamery
    Department of Anesthesiology, University Hospital of Geneva, Geneva, Switzerland
    Cytometry A 65:84-7. 2005
  6. ncbi Routine use of r-hFSH follitropin alfa filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK
    A Lass
    Serono Ltd, Feltham, Middlesex, London, UK
    Reprod Biomed Online 9:604-10. 2004
  7. ncbi The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors
    Jeffrey P Shaw
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Structure 12:2081-93. 2004
  8. ncbi Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in follicle-stimulating hormone-primed rats
    Sean D McKenna
    Serono Reproductive Biology Institute, Rockland, Massachusetts 02370, USA
    Endocrinology 146:208-14. 2005
  9. ncbi [Pharmacoeconomic advantages of recombinant FSH vs urinary derived FSH]
    A Beresniak
    Serono International SA, 15, Chemin des Mines, CH 1211, Genève 20, Suisse
    Gynecol Obstet Fertil 32:756-9. 2004
  10. ncbi Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs
    Rob Hooft van Huijsduijnen
    Serono Pharmaceutical Research Institute, Chemin des Aulx 14, 1228 Plan les Ouates, Geneva, Switzerland
    J Med Chem 47:4142-6. 2004

Scientific Experts

Detail Information

Publications62

  1. ncbi Treatment strategies in assisted reproduction for women of advanced maternal age
    Colin M Howles
    Serono International SA, Department of Product Development, Geneva, Switzerland
    Int Surg 91:S37-54. 2006
    ..Further studies are required to investigate the physiological mechanisms behind this observation and to assess the possible effect of LH and/or hGH supplementation on the age-related decline in pregnancy rate...
  2. ncbi Computational characterization of proteins
    Jadwiga Bienkowska
    Serono Reproductive Biology Institute, One Technology Pl, Rockland, MA 02370, USA
    Expert Rev Proteomics 2:129-38. 2005
    ..The authors point out the increasing importance of structural constraints and an increasing need to integrate different approaches...
  3. ncbi Bioequivalence of liquid and freeze-dried recombinant human follicle-stimulating hormone
    I Lugan
    International SA, R and Ph Development HPG, Geneva, Switzerland
    Curr Med Res Opin 21:121-5. 2005
    ....
  4. ncbi Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH
    R M Bassett
    Global Product Development Unit, Serono International SA, Geneva, Switzerland
    Reprod Biomed Online 10:169-77. 2005
    ..It also compares the analytical consistency of follitropin alfa FbM with another commercially available r-hFSH, follitropin beta...
  5. ncbi Flow cytometric analysis of CD41-labeled platelets isolated by the rapid, one-step OptiPrep method from human blood
    Krisztina Bagamery
    Department of Anesthesiology, University Hospital of Geneva, Geneva, Switzerland
    Cytometry A 65:84-7. 2005
    ..This work describes the rapid, one-step OptiPrep method for the isolation of highly purified platelets from human blood (buffy coat)...
  6. ncbi Routine use of r-hFSH follitropin alfa filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK
    A Lass
    Serono Ltd, Feltham, Middlesex, London, UK
    Reprod Biomed Online 9:604-10. 2004
    ..2% per cycle and 34.4% per embryo transfer. The routine use of r-hFSH follitropin alfa FbM in normal clinical practice in IVF has been demonstrated to be effective, safe and well received by patients...
  7. ncbi The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors
    Jeffrey P Shaw
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Structure 12:2081-93. 2004
    ..These crystallographic structures provide a description of the molecular interaction of a chemokine with glycosaminoglycans...
  8. ncbi Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in follicle-stimulating hormone-primed rats
    Sean D McKenna
    Serono Reproductive Biology Institute, Rockland, Massachusetts 02370, USA
    Endocrinology 146:208-14. 2005
    ..These results indicate that small molecule PDE4 inhibitors may be orally active alternatives to hCG as part of a fertility treatment regimen...
  9. ncbi [Pharmacoeconomic advantages of recombinant FSH vs urinary derived FSH]
    A Beresniak
    Serono International SA, 15, Chemin des Mines, CH 1211, Genève 20, Suisse
    Gynecol Obstet Fertil 32:756-9. 2004
    ..Different models have been carried out and published in several countries and present consistently that recombinant FSH is more cost-effective that urinary derived FSH...
  10. ncbi Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs
    Rob Hooft van Huijsduijnen
    Serono Pharmaceutical Research Institute, Chemin des Aulx 14, 1228 Plan les Ouates, Geneva, Switzerland
    J Med Chem 47:4142-6. 2004
  11. ncbi Cleaning protocols in the IVF laboratory
    Kay Elder
    Bourn Hall Clinic, Cambridge
    J Assist Reprod Genet 21:63-4. 2004
  12. ncbi Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs
    M D'Antonio
    Industria Farmaceutica Serono SpA, Drug Delivery Systems, Via Ribes 5, I 10010 Colleretto Giacosa, Turin, Italy
    Growth Horm IGF Res 14:226-34. 2004
    ..This new analogue might find therapeutic application in paediatric growth hormone deficiency or in aging...
  13. ncbi A search method for homologs of small proteins. Ubiquitin-like proteins in prokaryotic cells?
    Jadwiga R Bienkowska
    Serono Reproductive Biology Institute, One Technology Place, Rockland, MA 02370, USA
    Protein Eng 16:897-904. 2003
    ..This approach results in the identification of 90 probable ubiquitin-related proteins, including examples from the two prokaryotic domains of life, Archaea and Bacteria...
  14. ncbi Mitochondria and the Bcl-2 family proteins in apoptosis signaling pathways
    Bruno Antonsson
    Serono Pharmaceutical Research Institute, Geneva, Switzerland
    Mol Cell Biochem 256:141-55. 2004
    ..Although, apoptosis is an essential physiological process in multicellular organisms it is also involved in a wide range of pathological conditions...
  15. ncbi Comparative analytical characterization of two commercial human follicle-stimulating hormones extracted from human urine
    R Bassett
    Serono International SA, Geneva, Switzerland
    Curr Med Res Opin 21:899-905. 2005
    ..The aim of this study is to assess the purity of Folyrmon P and to compare it with Fertinorm-P, another commercial preparation of u-FSH-HP that has been available since 1993...
  16. ncbi Molecular pharmacology of gonadotropins
    Robert K Campbell
    Serono Research Institute, Rockland, MA 02370, USA
    Endocrine 26:291-6. 2005
    ..This could be facilitated by advances in biological models and the understanding of specific effects of the hormones on their receptors...
  17. ncbi G protein-coupled receptor-mediated ERK1/2 phosphorylation: towards a generic sensor of GPCR activation
    Didier Leroy
    Department of Molecular Screening and Cellular Pharmacology, Serono Pharmaceutical Research Institute, CH 1228 Plan les Ouates, Geneva, Switzerland
    J Recept Signal Transduct Res 27:83-97. 2007
    ..We propose the measurement of GPCR-activated ERK phosphorylation as an alternative assay to better understand the molecular pharmacology of ligands of promiscuous GPCRs...
  18. ncbi Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays
    Amer Jaber
    Laboratoires Serono SA, Zone Industrielle, CH 1267 Coinsins, Switzerland
    J Pharm Biomed Anal 43:1256-61. 2007
    ..05, RNF2 versus the current formulation). The immunogenic potential of RNF2 is significantly lower than that of the current formulation when tested ex vivo. This result is now being confirmed through ongoing clinical trials...
  19. ncbi A high-throughput mammalian protein expression, purification, aliquoting and storage pipeline to assemble a library of the human secretome
    Thierry Battle
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, CH 1228 Plan les Ouates, Geneva, Switzerland
    Comb Chem High Throughput Screen 9:639-49. 2006
    ..This article describes the major process steps and highlights the optimization required to maintain novel protein production while supporting both stock replenishment and scale-up productions...
  20. ncbi Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole
    Nerissa C Kreher
    Department of Pediatrics, Section of Pediatric Endocrinology and Diabetology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA
    J Pediatr 149:416-20. 2006
    ..Clinical improvements include decreased facial acne and pubic hair. Most importantly, a marked decrease in growth velocity and skeletal advancement has been achieved...
  21. ncbi Biological properties of a novel follicle-stimulating hormone/human chorionic gonadotropin chimeric gonadotropin
    Louise M Garone
    Serono Research Institute, Inc, One Technology Place, Rockland Massachusetts 02370, USA
    Endocrinology 147:4205-12. 2006
    ..In summary, the biological properties of C3 indicate that its chimeric nature has resulted in a fully functional, dual-acting human gonadotropin...
  22. ncbi Overcoming the hurdle of fluorescent compounds in kinase screening: a case study
    Dominique Perrin
    Molecular Screening and Cellular Pharmacology Department, Serono Pharmaceutical Research Institute, Geneva, Switzerland
    Assay Drug Dev Technol 4:185-96. 2006
    ..Results obtained seem to favor the nanofluidics mobility shift assay as a method of choice, followed by the direct FP approach, using generic high-molecular-weight phosphate group-binders...
  23. ncbi Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis
    C M Howles
    Serono Singapore Pte, Singapore
    Curr Med Res Opin 22:907-18. 2006
    ....
  24. ncbi An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection]
    Sandra L Blethen
    Medical Affairs, Serono Inc, Rockland, MA 02370, USA
    Pediatr Endocrinol Rev 2:324-6. 2005
    ..Most were self-limited but 13 were serious, and 5 resulted in discontinuation of treatment. Data from The GHMonitor provide a real world glimpse of current North American GH treatment practices...
  25. ncbi Factors influencing response to ovarian stimulation
    Christoph Keck
    Serono International, Geneva, Switzerland
    Reprod Biomed Online 11:562-9. 2005
    ..This is an important step towards further minimizing drug-related variability of ovarian response to FSH treatment...
  26. ncbi A network model for the control of the differentiation process in Th cells
    Luis Mendoza
    Serono Pharmaceutical Research Institute, 14, Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Biosystems 84:101-14. 2006
    ..The stable steady states of the Th network model are consistent with the stable molecular patterns of activation observed in wild type and mutant Th0, Th1 and Th2 cells...
  27. ncbi Staff management in the in vitro fertilization laboratory
    Christoph Keck
    Serono International, Geneva, Switzerland
    Fertil Steril 84:1786-8. 2005
    ..This article describes methods for staff development and monitoring of staff performance in the IVF laboratory...
  28. ncbi Chemokine blockers--therapeutics in the making?
    Timothy N C Wells
    Serono Pharmaceutical Research Institute, 1228 Plan les Ouates, Geneva, Switzerland
    Trends Pharmacol Sci 27:41-7. 2006
    ..Here, we describe the rationale behind these different approaches, the pitfalls that have been encountered and future perspectives...
  29. ncbi Tumor necrosis factor (TNF)-soluble high-affinity receptor complex as a TNF antagonist
    Sean D McKenna
    Serono Research Institute, Rockland, Massachusetts 02370, USA
    J Pharmacol Exp Ther 322:822-8. 2007
    ..Based on these results, we demonstrated that inactivated heterodimeric protein hormones are flexible and efficient scaffolds for the creation of soluble high-affinity receptor complexes...
  30. ncbi Drug discovery and development for metabolic diseases
    Rob Hooft
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Drug Discov Today 8:1064-6. 2003
  31. ncbi Recombinant human follicle-stimulating hormone versus urinary-derived human menopausal gonadotropin for controlled ovarian stimulation: the science and art of assisted reproductive technologies
    Eduardo Kelly
    Serono, Inc, Rockland, Massachusetts 02370, USA
    Fertil Steril 80:1105-7. 2003
  32. ncbi The voltage-dependent anion channel is the target for a new class of inhibitors of the mitochondrial permeability transition pore
    Andrea M Cesura
    Pharmaceutical Division, Drug Discovery Department, F Hoffmann La Roche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland
    J Biol Chem 278:49812-8. 2003
    ..While Ro 68-3400 represents a new useful tool for the study of the structure and function of VDAC and the PTP, the results obtained provide direct evidence that VDAC1 is a component of this mitochondrial pore...
  33. ncbi How do patients choose private in vitro fertilization treatment? A customer survey in a tertiary fertility center in the United Kingdom
    A Lass
    Bourn Hall Clinic, Bourn, Cambridge, United Kingdom
    Fertil Steril 75:893-7. 2001
    ..To assess the relevant factors affecting patients' decision when choosing a clinic for private, self-funded IVF treatment...
  34. ncbi Prions: disease propagation and disease therapy by conformational transmission
    C Soto
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Trends Mol Med 7:109-14. 2001
    ..Here, we describe exciting scientific findings that make the prion field attractively heretical, and we propose the transmission of protein conformation as a novel approach to producing drugs to combat a variety of diseases...
  35. ncbi Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains
    X Espanel
    Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Biol Chem 276:14514-23. 2001
    ..Since overexpression of an activated form of c-Yes resulted in tyrosine phosphorylation of p53BP-2, we propose that the p53BP-2 phosphorylation, possibly in the WW1 domain-binding motif, might negatively regulate the YAP.p53BP-2 complex...
  36. ncbi Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy
    C Soto
    Serono Pharmaceutical Research Institute, Geneva, Switzerland
    Acta Neurol Scand Suppl 176:90-5. 2000
    ..It remains to be proved that inhibition of the defective folding of amyloid-beta peptide and/or amyloid plaque deposition could be beneficial for the therapeutic treatment of Alzheimer's disease...
  37. ncbi Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells
    B Antonsson
    Serono Pharmaceutical Research Institute, Serono International S A, 14 Chemin des Aulx, CH 1228 Plan les Ouates, Geneva, Switzerland
    J Biol Chem 276:11615-23. 2001
    ..Bax oligomerization appears to be required for its proapoptotic activity, and the Bax oligomer/complex might constitute the structural entirety of the cytochrome c-conducting channel in the outer mitochondrial membrane...
  38. ncbi Mapping and identification of protein-protein interactions by two-dimensional far-Western immunoblotting
    C Pasquali
    Serono Pharmaceutical Research Institute, Geneva, Switzerland
    Electrophoresis 21:3357-68. 2000
    ..We believe that this method could be generally applied to identify possible protein-protein interactions...
  39. pmc Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria
    B Antonsson
    Serono Pharmaceutical Research Institute, Ares Serono International S A, 14, Chemin des Aulx, CH 1228 Plan les Ouates, Geneva, Switzerland
    Biochem J 345:271-8. 2000
    ..These results show that oligomeric Bax possesses channel-forming activity whereas monomeric Bax has no such activity...
  40. ncbi The fertility potential of women with a single ovary
    A Lass
    Bourn Hall Clinic, Cambridge, UK
    Hum Reprod Update 5:546-50. 1999
    ..This article reviews the effect of possessing a single ovary on the fertility potential and ovarian reserve of these women and their performance in assisted reproduction treatment...
  41. ncbi Chemokine receptors and their antagonists in allergic lung disease
    T N Wells
    Serono Pharmaceutical Research Institute, Geneva, Switzerland
    Inflamm Res 48:353-62. 1999
    ..The data so far obtained in animal studies point to the potential clinical uses of this emerging class of therapeutic agents...
  42. ncbi Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease
    C Soto
    University of Chile Dept of Biology, Faculty of Sciences, Las Palmeras 3425, Santiago, Chile
    Mol Med Today 5:343-50. 1999
    ..The effect of these and other compounds now needs to be tested in vivo and the ability of amyloid inhibitors to halt the progression of Alzheimer's disease in humans needs to be evaluated...
  43. ncbi Bcl-2 family members in the development and degenerative pathologies of the nervous system
    R Sadoul
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Cell Death Differ 5:805-15. 1998
    ..In this review, I will discuss the possible mechanisms of action of these proteins as well as their potential use in treating neurodegenerative diseases...
  44. ncbi One thousand initiated cycles of in vitro fertilization in women > or = 40 years of age
    A Lass
    Institute of Obstetrics and Gynecology, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom
    Fertil Steril 70:1030-4. 1998
    ..To evaluate the results of IVF in women > or = 40 years of age using their own oocytes...
  45. ncbi Induction of the mitogen-activated protein kinase phosphatase MKP3 by nerve growth factor in differentiating PC12
    M Camps
    Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development S A, Switzerland
    FEBS Lett 425:271-6. 1998
    ....
  46. ncbi Assessment of ovarian reserve - is there a role for ovarian biopsy?
    A Lass
    Bourn Hall Clinic, Bourn, Cambridge CB3 7TR, UK
    Hum Reprod 16:1055-7. 2001
    ..In this manuscript, a novel approach of histopathological examination of ovarian biopsy for the evaluation of infertility, especially in unexplained infertility and in women in the later part of reproductive life, is discussed...
  47. ncbi Sperm banking and assisted reproduction treatment for couples following cancer treatment of the male partner
    A Lass
    Bourn Hall Clinic, Cambridg, UK
    Hum Reprod Update 7:370-7. 2001
    ..The authors believe in the importance of protecting the fertility potential of cancer patients, enabling them to father their genetic children in the future while fighting their illness...
  48. ncbi [RecDate - an IT-solution for the documentation and quality management of reproductive medicine]
    S J Pak
    Serono Pharma GmbH, Unterschleissheim, Germany
    Zentralbl Gynakol 123:482-6. 2001
    ..The aim of this paper was to describe the possible use of the software RecDate für documentation and Quality Management in Reproductive Medicine...
  49. ncbi IL-18 binding protein protects against contact hypersensitivity
    Thomas Plitz
    Department of Immunology, Serono Pharmaceutical Research Institute, Geneva, Switzerland
    J Immunol 171:1164-71. 2003
    ..Taken together with the evidence that IL-18 is present in tissue samples of the human disease, our data reinforces IL-18BP as a candidate for this therapeutic indication...
  50. ncbi Protein Phosphorylation Drug Discovery Summit--SRI conference. Targeting kinases and phosphatases for novel therapeutics. 3-5 March 2003, San Diego, CA, USA
    Rob Hooft
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    IDrugs 6:312-4. 2003
  51. ncbi Comparison of recombinant human luteinising hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology
    G Baer
    Laboratoires Serono, Vevey, Switzerland
    Curr Med Res Opin 19:83-8. 2003
    ..r-hLH therefore provides the clinician with the opportunity for precise and consistent dosing within the therapeutic window for patients requiring exogenous LH, without the risk of LH overexposure that is associated with hCG...
  52. ncbi Glycosylation of human recombinant gonadotrophins: characterization and batch-to-batch consistency
    Annick Gervais
    Laboratoires Serono SA, Serono Biotech Center, Zone Industrielle B, CH 1809 Fenil sur Corsier, Switzerland
    Glycobiology 13:179-89. 2003
    ....
  53. ncbi Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance
    Gordon S Francis
    Serono Inc, Rockland, Massachusetts, USA
    Drug Saf 26:815-27. 2003
    ..Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited...
  54. ncbi Knock out models to dissect chemokine receptor function in vivo
    Christine A Power
    Serono Pharmaceutical Research Institute, 14, Chemin des Aulx, 1228, Plan les Ouates, Geneva, Switzerland
    J Immunol Methods 273:73-82. 2003
    ..Therefore, targeted deletion of chemokine receptors has proved to be a useful tool for determining the distinct biological role of these molecules in vivo...
  55. ncbi Unfolding the role of protein misfolding in neurodegenerative diseases
    Claudio Soto
    Serono International, 15 Chemin des Mines, Geneva, Switzerland
    Nat Rev Neurosci 4:49-60. 2003
  56. ncbi Altering prion replication for therapy and diagnosis of transmissible spongiform encephalopathies
    C Soto
    Serono International, Geneva, Switzerland
    Biochem Soc Trans 30:569-74. 2002
    ..In this article, the potential use of the principles of prion replication to develop novel therapeutic and diagnostic strategies for these devastating diseases are described...
  57. ncbi Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1
    Angela Romanelli
    Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    J Biol Chem 277:40281-9. 2002
    ....
  58. ncbi Chemokine receptors: multifaceted therapeutic targets
    Amanda E I Proudfoot
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Nat Rev Immunol 2:106-15. 2002
    ..Here, I focus on the rationale for developing antagonists of chemokine receptors for inflammatory disorders and AIDS, and the accumulating evidence that favours this strategy despite the apparent redundancy in the chemokine system...
  59. ncbi Set-up of large laboratory-scale chromatographic separations of poly(ethylene glycol) derivatives of the growth hormone-releasing factor 1-29 analogue
    G Piquet
    Istituto di Ricerca Cesare Serono, Drug Delivery Systems, Bioconjugates development and scale up department, BioIndustry Park del Canavese, Turin, Italy
    J Chromatogr A 944:141-8. 2002
    ..Overall, the gram GRF equivalent/batch process scale showed to be quite reproducible, and could be considered as a good platform for scale up to production scale...
  60. ncbi Biotechnology partnerships--medicine for an ailing industry?
    John DeLamarter
    Serono, Geneva, Switzerland
    Nat Biotechnol 21:847-8. 2003
  61. ncbi Selecting protein tyrosine phosphatases as drug targets
    Rob Hooft van Huijsduijnen
    Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland
    Drug Discov Today 7:1013-9. 2002
    ....
  62. ncbi Splice variants of the relaxin and INSL3 receptors reveal unanticipated molecular complexity
    Marco Muda
    Serono Research Institute, One Technology Place, Rockland, MA 02370, USA
    Mol Hum Reprod 11:591-600. 2005
    ..The large number of receptor splice variants identified suggests an unforeseen complexity in the physiology of this novel hormone-receptor system...